292 related articles for article (PubMed ID: 28432119)
1. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
3. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
5. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
[TBL] [Abstract][Full Text] [Related]
6. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Dillard TH; Gultekin SH; Delashaw JB; Yedinak CG; Neuwelt EA; Fleseriu M
Pituitary; 2011 Mar; 14(1):80-91. PubMed ID: 20972839
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
[TBL] [Abstract][Full Text] [Related]
10. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
McCormack A; Dekkers OM; Petersenn S; Popovic V; Trouillas J; Raverot G; Burman P;
Eur J Endocrinol; 2018 Mar; 178(3):265-276. PubMed ID: 29330228
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U; Schlaffer SM; Buchfelder M; Knappe UJ; Vila G; Micko A; Deutschbein T; Unger N; Lammert A; Topuzoglu-Müller T; Bojunga J; Droste M; Johanssen S; Kolenda H; Ritzel K; Buslei R; Strasburger CJ; Petersenn S; Honegger J
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31746334
[TBL] [Abstract][Full Text] [Related]
12. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
16. Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series.
Padovan M; Cerretti G; Caccese M; Barbot M; Bergo E; Occhi G; Scaroni C; Lombardi G; Ceccato F
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):181-198. PubMed ID: 36876325
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Kamiya-Matsuoka C; Cachia D; Waguespack SG; Crane CH; Mahajan A; Brown PD; Nam JY; McCutcheon IE; Penas-Prado M
Pituitary; 2016 Aug; 19(4):415-21. PubMed ID: 27106209
[TBL] [Abstract][Full Text] [Related]
18. How effective is temozolomide for treating pituitary tumours and when should it be used?
Halevy C; Whitelaw BC
Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
[TBL] [Abstract][Full Text] [Related]
20. Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Bilbao I; Egaña N; García C; Olaizola I
Endocrinol Diabetes Nutr; 2017 Dec; 64(10):564-566. PubMed ID: 29137963
[No Abstract] [Full Text] [Related]
[Next] [New Search]